Your browser doesn't support javascript.
loading
Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial.
Bos, Eelke M; Binda, Elena; Verploegh, Iris S C; Wembacher, Eva; Hoefnagel, Daphna; Balvers, Rutger K; Korporaal, Anne L; Conidi, Andrea; Warnert, Esther A H; Trivieri, Nadia; Visioli, Alberto; Zaccarini, Paola; Caiola, Laura; van Wijck, Rogier; van der Spek, Peter; Huylebroeck, Danny; Leenstra, Sieger; Lamfers, Martine L M; Ram, Zvi; Westphal, Manfred; Noske, David; Legnani, Federico; DiMeco, Francesco; Vescovi, Angelo Luigi; Dirven, Clemens M F.
Afiliação
  • Bos EM; Department of Neurosurgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Binda E; Unit of Cancer Stem Cells, ISBReMIT, IRCCS CasaSollievo della Sofferenza, San Giovanni Rotondo (FG), Italy.
  • Verploegh ISC; Department of Neurosurgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Wembacher E; Department of Cell Biology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Hoefnagel D; Brainlab A.G., Munich, Germany.
  • Balvers RK; Department of Neurosurgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Korporaal AL; Department of Neurosurgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Conidi A; Department of Cell Biology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Warnert EAH; Department of Cell Biology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Trivieri N; Department of Radiology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Visioli A; Unit of Cancer Stem Cells, ISBReMIT, IRCCS CasaSollievo della Sofferenza, San Giovanni Rotondo (FG), Italy.
  • Zaccarini P; StemGen SpA, Milan, Italy.
  • Caiola L; HyperStem SA, Lugano, Switzerland.
  • van Wijck R; StemGen SpA, Milan, Italy.
  • van der Spek P; HyperStem SA, Lugano, Switzerland.
  • Huylebroeck D; StemGen SpA, Milan, Italy.
  • Leenstra S; HyperStem SA, Lugano, Switzerland.
  • Lamfers MLM; Department of Clinical Bioinformatics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Ram Z; Department of Clinical Bioinformatics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Westphal M; Department of Cell Biology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Noske D; Department of Neurosurgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Legnani F; Department of Neurosurgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • DiMeco F; Department of Neurosurgery, Tel Aviv Medical Center, Tel Aviv, Israel.
  • Vescovi AL; Department of Neurosurgery, University Clinic Hamburg-Eppendorf, Hamburg, Germany.
  • Dirven CMF; Department of Neurosurgery, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Mol Cancer ; 22(1): 129, 2023 08 10.
Article em En | MEDLINE | ID: mdl-37563568
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Mol Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Mol Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda País de publicação: Reino Unido